基石药业：普吉华纳入2025年国家医保目录

Core Viewpoint - The inclusion of the drug Pujihua® (Pralsetinib capsules, 100mg) in the latest National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List by China's National Healthcare Security Administration is a significant development for the company, effective from January 1, 2026 [1] Company Summary - Pujihua® is an oral, once-daily targeted therapy medication [1]